Moneycontrol
Get App
Last Updated : Sep 11, 2019 12:05 PM IST | Source: Moneycontrol.com

Sanofi India declines 2% on sale of Ankleshwar unit

This transaction is subject to shareholders’ approval and the completion of certain conditions as defined under the business transfer agreement.

Moneycontrol News @moneycontrolcom
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Shares of Sanofi India declined more than 2 percent intraday on September 11 after the company approved sale of its Ankleshwar unit.

The company board approved a transaction for the slump sale and transfer of its manufacturing facility at Ankleshwar, Gujarat to Zentiva and its legal entity in India, Zentiva Private Limited for a consideration of Rs 261.7 crore, subject to customary working capital adjustments.

This transaction is subject to shareholders’ approval and the completion of certain conditions as defined under the business transfer agreement.

Close

Rajaram Narayanan, Managing Director, Sanofi India said, “Sanofi’s long-term strategy is to focus on manufacturing Sanofi branded products. Given that the two companies share similar values and commitment towards serving patients and their employees, the board of directors of Sanofi India approved this transaction in the long-term interest of all stakeholders."

At 1149 hrs, Sanofi India was quoting at Rs 6,120, down Rs 143.80, or 2.30 percent on the BSE.

Get access to India's fastest growing financial subscriptions service Moneycontrol Pro for as little as Rs 599 for first year. Use the code "GETPRO". Moneycontrol Pro offers you all the information you need for wealth creation including actionable investment ideas, independent research and insights & analysis For more information, check out the Moneycontrol website or mobile app.
First Published on Sep 11, 2019 12:05 pm
Loading...
Sections
Follow us on
Available On
PCI DSS Compliant